Contrast agent development firm Alerion Biomedical of San Diego, in collaboration with the Vanderbilt University Medical Center in Nashville, TN, has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a project involving MRI with protease-sensing contrast agents.
The goals of the STTR project include designing, synthesizing, and testing a new class of biochemically activated MRI contrast agents that detect and monitor disease-associated enzymatic activity in vivo. The project has the potential to improve the noninvasive detection and evaluation of cancer, Alerion said.
By AuntMinnie.com staff writers
January 5, 2005
Copyright © 2005 AuntMinnie.com
